A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

In a year when eradicated diseases are on the uptick in America, how will American children survive RFK Jr.’s vaccine ...

Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...

While sparking excitement among biopharma companies focused on rare and ultrarare indications, experts say FDA Commissioner ...

Sponsored communities reduce timelines and increase relevance. Digital engagement allows for rapid study launches and ...

While the Trump administration has painted the jettisoning of staff and regulations as good for business, there are multiple ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...